News & Resources


Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.03 (0.79%)
Aug 26, 2016 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
08/04/16Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016Printer Friendly Version
08/01/16Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales OrganizationPrinter Friendly Version
08/01/16Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios Farmacéuticos Rovi, S.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in SpainPrinter Friendly Version
07/21/16Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2016 Financial Results on August 4, 2016Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.